Abstract
Background: Results of therapy in patients with unstable coronary syndromes with antibiotics directed against Chlamydia pneumoniae have been variable, perhaps due to the heterogeneity of patients in these trials.
Hypothesis: The aim of the present study was to correlate the severity of coronary artery disease (CAD) with seropositivity against C. pneumoniae prospectively.
Methods: We measured the frequency of seropositivity (IgG levels ≥ 1/64 and IgA levels ≥ 1/16 against Chlamydia pneumoniae) in 110 patients with CAD and in 49 controls.
Results: As expected, traditional CAD risk factors were seen more often in patients with CAD than in controls. Mean values of total cholesterol (184 ± 52 and 166 ± 44 mg/dl, respectively) and triglyceride (143 ± 60 and 112 ± 63 mg/dl, respectively) in serum were significantly higher in patients with CAD than in controls (both p < 0.04). There were no significant differences between the two groups in serum high‐density lipoprotein cholesterol (34 ± 13 and 32 ± 14 mg/dl, respectively) and lipoprotein (a) (Lp(a):241 ± 247 and 223 ± 263 mg/l, respectively) levels. The rate of IgG seropositivity was 52% (28/54) in patients with stable CAD, 41% (23/56) in patients with unstable CAD, and 35% in controls (p = NS). The rate of IgA seropositivity was 25% (14/54) in patients with stable CAD, 12% (6/49) in patients with unstable angina, and 12% (6/49) in controls (all p = NS).
Conclusions: Only a small percentage of patients with CAD demonstrate seropositivity against Chlamydia pneumoniae. Antibiotic therapy in these selected patients, but not in the remaining patients, may be considered rational. These considerations may underlie the failure to see consistent benefits of antibiotic therapy in patients with CAD.
Keywords: Chlamydia pneumoniae, coronary artery disease, seropositivity
Full Text
The Full Text of this article is available as a PDF (412.3 KB).
Reference
- 1. Mehta JL, Saldeen TGP, Rand K: Interactive role of infection, inflammation, and traditional risk factors in atherosclerosis and coronary artery disease. J Am Coll Cardiol 1998; 31: 1217–1225 [DOI] [PubMed] [Google Scholar]
- 2. Dahlén GH, Boman J, Birgander LS, Lindblom B: Lp(a) lipoprotein, IgG, IgA and IgM antibodies to Chlamydia pneumoniae and HLA class II genotype in early coronary artery disease. Atherosclerosis 1995; 114: 165–174 [DOI] [PubMed] [Google Scholar]
- 3. Saikku P, Mattila K, Nieminen MS, Huttonen JK, Leinonen MI, Ekman MR, Makela PH, Valtonen V: Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988; 2: 983–986 [DOI] [PubMed] [Google Scholar]
- 4. Thom DH, Wang SP, Grayston JT, Siscovick S, Stewart DK, Kronmal RA, Weiss NS: Chlamydia pneumoniae strain TWAR antibody and angiographically demonstrated coronary artery disease. Arterioscler Thromb 1991; 11: 547–551 [DOI] [PubMed] [Google Scholar]
- 5. Gaydos CA, Summersgill JT, Sahney NN, Ramirez JA, Quinn TC: Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells. Infect Immun 1996; 64: 1614–1620 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Wyrick PB, Brunridge EA: Growth of Chlamydia psittaci in macrophages. Infect Immun 1978; 19: 1054–1060 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Godzik KL, O'Brien ER, Wang SK, Kuo CC: In vitro susceptibility of human vascular wall cells to infection with Chlamydia pneumoniae. J Clin Microbiol 1995; 33: 2411–2414 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Muhlestein JB, Anderson JL, Hammond EH, Zhao L, Trehan S, Schwobe EP, Carlquist JF: Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 1998; 97: 633–636 [DOI] [PubMed] [Google Scholar]
- 9. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ: Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of acute myocardial infarction. Circulation 1997; 96: 404–407 [DOI] [PubMed] [Google Scholar]
- 10. Gurfunkel E, Bozovich G, Daroca A, Beck E, Mautner B: Randomised trial of roxithromycin in non‐Q‐wave coronary syndromes. Lancet 1997; 350: 404–407 [DOI] [PubMed] [Google Scholar]
- 11. Anderson JL, Muhlestein JB, Carlquist J, Allen A, Trehan S, Nielson C, Hall S, Brady J, Egger M, Horne B, Lim T: Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. Circulation 1999; 99: 1540–1547 [DOI] [PubMed] [Google Scholar]
- 12. Altman R, Rouvier J, Scazziota A, Absi RS, Gonzalez C: Lack of association between prior infection with Chlamydia pneumoniae and acute or chronic coronary artery disease. Clin Cardiol 1999; 22: 85–90 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Maass M, Gieffers J, Krause E, Engel PM, Bartels C, Solbach W: Poor correlation between microimmunofluorescence serology and polymerase chain reaction for detection of vascular Chlamydia pneumoniae infection in coronary artery disease patients. Med Microbiol Immunol (Berl) 1998; 187: 103–106 [DOI] [PubMed] [Google Scholar]
- 14. Anderson JL, Carlquist JF, Muhlestein JB, Home BD, Elmer SP: Evaluation of C‐reactive protein, an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction. J Am Coll Cardiol 1998; 32: 35–41 [DOI] [PubMed] [Google Scholar]
- 15. Kark JD, Leinonen M, Paltiel O, Saikku P: Chlamydia pneumoniae and acute myocardial infarction in Jerusalem. Int J Epidemiol 1997; 26: 730–738 [DOI] [PubMed] [Google Scholar]
- 16. Weiss SM, Roblin PM, Gaydos CA, Cummings P, Patton DL, Schulhoff N, Shani J, Frankel R, Penny K, Quinn TC, Hammerschlag MD, Schachter J: Failure to detect Chlamydia pneumoniae in coronary atheromas of patients undergoing atherectomy. J Infect Dis 1996; 173: 957–962 [DOI] [PubMed] [Google Scholar]
- 17. Moazed TC, Kuo C, Grayston JT, Campbell LA: Murine models of Chlamydia pneumoniae infection and atherosclerosis. J Infect Dis 1997; 175: 883–890 [DOI] [PubMed] [Google Scholar]
- 18. Shor A, Kuo CC, Patton DL: Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques. S Afr Med J 1992; 82: 158–161 [PubMed] [Google Scholar]
- 19. Kuo CC, Grayston JT, Campbell LA, Goo YA, Wissler RW, Beneditt EP: Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15–34 year old). Proc Natl Acad Sci USA 1995; 92: 6911–6914 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Campbell LA O'Brien ER, Cappuccio AL, Kuo C‐C, Wang S‐P, Stewart D, Grayston JT: Detection of Chlamydia pneumoniae TWAR in human coronary atherectomy tissues. J Infect Dis 1995; 172: 585–588 [DOI] [PubMed] [Google Scholar]
- 21. Ong G, Thomas BJ, Mansfield AO, Davidson BR, Taylor‐Robinson D: Detection and widespread distribution of Chlamydia pneumoniae in the vascular system and its possible implications. J Clin Path 1996; 49: 102–106 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Muhlestein JB, Hammond EH, Carlquist JF, Radicke E, Thomson MJ, Karnqounis LA, Woods ML, Anderson JL: Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J Am Coll Cardiol 1996; 27: 1555–1561 [DOI] [PubMed] [Google Scholar]
- 23. Ramirez JA: Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis: The Chlamydia pneumoniae/Atherosclerosis Study Group. Ann Intern Med 1996; 125: 979–982 [DOI] [PubMed] [Google Scholar]
- 24. Saldeen TGP, Ericsson K, Lindquist O, Pahlson C, Lindblom B, Liu AJ, Mehta JL: Chlamydia and HLA‐DR genotypes in coronary atherosclerosis (abstr). J Am Coll Cardiol 1998; 31: 272A [Google Scholar]
- 25. Fryer RH, Schwobe EP, Woods ML, Rodgers GM: Chlamydia species infect human vascular endothelial cells and induce procoagulant activity. J Invest Med 1997; 45: 168–174 [PubMed] [Google Scholar]
- 26. Cleeman JI, Lenfant C: National Cholesterol Education Program: Progress and prospects. J Am Med Assoc 1998; 280: 2099–2104 [DOI] [PubMed] [Google Scholar]
- 27. Hajjar DP, Pomerantz KB, Falcone DJ, Weksler BB, Grant AJ: Herpes simplex virus infection in human arterial cells. Implications in atherosclerosis. J Clin Invest 1987; 80: 1317–1321 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Hu H, Pierce GN, Zhong G: The atherogenic effects of Chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae. J Clin Invest 1999; 103: 747–753 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Murray LJ, O'Reilly DP, Ong GM, O'Neill C, Evans AE, Bamford KB: Chlamydia pneumoniae antibodies are associated with an atherogenic lipid profile. Heart 1999; 81: 239–244 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30. Laurila A, Bloigu A, Nayha S, Hassi J, Leinonen M, Saikku P: Chronic Chlamydia pneumoniae infection is associated with a serum lipid profile known to be a risk factor for atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17: 2910–2913 [DOI] [PubMed] [Google Scholar]
- 31. Hoffmeister A, Rothebachor D, Wanner P, Boda G, Persson K, Brenner H, Hombach V, Koenig W: Systemic inflammation, serpositivity to Chlamydial lipopolysaceharide and coronary artery disease—a case control study (abstr). Circulation 1998; I–602 [DOI] [PubMed]
- 32. Ridker PM, Kundin RB, Stampfer MJ, Poulin S, Hennekens CM: A prospective study of Chlamydia pneumoniae IgG serpositivity and risk of future myocardial infarction (abstr). Circulation 1998; I–602 [DOI] [PubMed]